Merion Technologies (MIR) Q1 2026: Orders Surge 42% as Nuclear Tailwinds Expand $1.1B Backlog
Merion Technologies’ first quarter revealed a decisive inflection in nuclear demand, driving a 42% order surge and record backlog expansion. The integration of Paragon and Certrek is yielding early synergy wins, positioning Merion as the most comprehensive U.S. nuclear solutions provider. With nuclear power reinvestment accelerating and medical segment headwinds easing, the company’s multi-year growth visibility is strengthening beyond 2026.
Summary
- Nuclear Reinvestment Accelerates: U.S. and global operators shift from shutdowns to 100-year asset cycles, fueling demand for modernization.
- Integrated Platform Advantage: Paragon and Certrek acquisitions deliver early cross-sell wins and expand addressable market.
- Multi-Year Backlog Visibility: Expanding project pipeline and early large order wins improve revenue clarity into 2027.
Performance Analysis
Merion’s Q1 2026 performance was defined by a step-change in order intake and backlog, not just revenue growth. Total orders climbed 42% to $288 million, including Paragon and Certrek, with organic orders up 19%. This translated to a backlog of $1.1 billion, up 19% excluding M&A and 38% including it—a critical signal of future revenue acceleration. The company’s nuclear and safety segment led growth, boosted by both installed base and SMR (Small Modular Reactor) demand, while the medical segment rebounded from prior year headwinds.
Organic revenue growth of 3% was within expectations, but the strategic narrative is dominated by the order pipeline and backlog expansion. Paragon contributed 45% revenue growth, and its integration is already delivering incremental order wins and customer access. Margins contracted, as flagged, due to the dilutive impact of recent acquisitions and mix effects, but management reaffirmed margin expansion in the legacy business for the remainder of the year. Cash flow was seasonally light, with expectations for stronger generation ahead as project timing normalizes.
- Nuclear Power Demand Shift: Installed base upgrades and SMR projects are driving order momentum, with more than 80% of nuclear revenue tied to the existing fleet.
- Medical Segment Recovery: RTQA and software orders showed green shoots, and backlog from the Varian partnership supports future growth.
- Margin Profile Dynamics: Near-term margin contraction from M&A is offset by operating leverage and pricing upside in core businesses.
Merion’s results signal a structural tailwind in nuclear and growing confidence in medical, setting up for multi-year growth as backlog converts to revenue.
Executive Commentary
"The accelerating nuclear power demand we see is reflective of increasing market tailwinds. The momentum continues to compound, and recent geopolitical events reinforce the need for onshore secure baseload energy. ... Back-to-back strong Q4 and Q1 orders are creating a step change in our backlog. After two years of nominal backlog growth, the nuclear dynamic we've been discussing is translating into tangible opportunities for our company."
Tom Logan, Founder, Chairman, and CEO
"Order performance was the highlight of the quarter. Absent any M&A-related order growth, core orders grew nearly 20%, reflecting growth in both segments. ... We remain on track for our full year adjusted free cash flow guidance and believe Q1 marks a trough. We continue to see large opportunities for improvement in AR, inventory, and our project cash flows."
Brian Shopper, CFO and Medical Group President
Strategic Positioning
1. Nuclear Power: Installed Base and SMR Upside
Merion’s installed base nuclear business, accounting for over 80% of segment revenue, is benefiting from a structural shift among operators toward 100-year asset lives and modernization cycles. The company’s content in nearly every North American reactor and 98% of the global fleet positions it as a critical supplier as utilities accelerate capital deployment. SMR orders are emerging as a high-growth, higher-margin opportunity, with recent large wins and revenue per megawatt estimated at 60% above utility scale projects.
2. Paragon and Certrek Integration: Platform Synergy
The Paragon and Certrek acquisitions are unlocking cross-sell and commercial synergy opportunities, creating a uniquely integrated offering across hardware, software, and services. Paragon’s sales relationships are driving incremental legacy product wins, while Certrek’s regulatory and workforce software is expanding recurring revenue. The integration is already producing tangible backlog growth and deeper customer intimacy, described by management as a “tip of the spear” advantage.
3. Medical Segment: Recovery and Digital Expansion
After a challenging 2025, the medical segment is showing signs of stabilization and renewed growth, with RTQA hardware and software leading order momentum. The Varian partnership has delivered a sizable camera order, and software continues to be a bright spot. Nuclear medicine remains on track for double-digit organic growth, and digital dosimetry is opening cross-sell opportunities into nuclear markets.
4. Margin Expansion Roadmap
Despite near-term margin dilution from M&A, Merion’s long-term EBITDA margin target of 30% by 2028 remains intact. Management expects operating leverage, procurement optimization, and digitalization—including AI investment—to drive margin recovery and expansion. The company’s track record, exemplified by the Sun Nuclear acquisition, supports this outlook.
Key Considerations
The quarter marked a structural inflection in nuclear demand and backlog, with critical implications for Merion’s multi-year growth trajectory. Strategic positioning, order visibility, and integration execution are central themes for investors.
Key Considerations:
- Structural Nuclear Tailwind: U.S. and global policy shifts, energy security concerns, and AI-driven power demand are driving a new cycle of nuclear investment.
- Backlog Conversion Timing: Backlog expansion provides revenue visibility, but project timing and order lumpiness will affect quarterly results.
- Integration Execution Risk: Realizing synergy from Paragon and Certrek is critical to sustaining commercial momentum and margin improvement.
- Medical Segment Variability: While RTQA and software are improving, Asian markets and hardware orders remain watchpoints for sustained recovery.
Risks
Execution on large project backlogs and integration of recent acquisitions are key risks, as is the inherent lumpiness in nuclear and medical project timing. Margin dilution from M&A and potential delays in new build or SMR projects could pressure near-term results. Geopolitical and regulatory shifts, especially in energy policy, remain material variables for the nuclear end market.
Forward Outlook
For Q2 2026, Merion guided to:
- 15% to 20% sequential order growth over Q1, reflecting continued nuclear and SMR momentum
- Low single-digit consolidated organic revenue growth, with similar trends in both segments
For full-year 2026, management maintained guidance:
- Double-digit nuclear power revenue growth (pre-Paragon)
- Paragon revenue up ~25% YoY, with low 20s EBITDA margins
- Continued margin expansion in the legacy business, offset by M&A dilution
Management emphasized growing confidence in order visibility and backlog conversion, with large project wins now occurring earlier in the year. Backlog growth is expected to continue in Q2, and medical segment conviction is improving, though guidance remains unchanged for now.
Takeaways
Merion’s Q1 2026 results confirm a generational inflection in nuclear demand, with order and backlog growth supporting multi-year revenue visibility. Integration of Paragon and Certrek is already delivering commercial and operational synergies, while the medical segment is stabilizing after prior headwinds.
- Nuclear Cycle Inflection: Policy and market shifts are driving a sustained reinvestment cycle, with Merion’s installed base exposure and SMR wins positioning the company ahead of peers.
- Synergy Realization: Early cross-sell wins and deeper customer engagement validate the Paragon and Certrek acquisition strategy, but integration execution remains a watchpoint.
- Backlog Converts to Growth: With a record backlog and robust order pipeline, Merion’s revenue and margin trajectory is increasingly visible into 2027, contingent on execution and project timing.
Conclusion
Merion Technologies enters 2026 with accelerating nuclear tailwinds, a record backlog, and strengthening medical segment momentum. The company’s integrated platform and strategic end-market exposure support a positive multi-year outlook, though margin and integration execution will be critical for unlocking full value.
Industry Read-Through
Merion’s results reinforce a broad-based nuclear energy renaissance, with utilities globally shifting from plant shutdowns to modernization and capacity expansion. The company’s experience with SMR order momentum and installed base upgrades signals a durable capital cycle for nuclear OEMs, engineering firms, and digital solution providers. Medical segment stabilization and digitalization trends also bode well for peers exposed to radiopharma, digital dosimetry, and RTQA. Investors across industrials, energy, and healthcare should monitor the multi-year capital commitment to nuclear infrastructure, as well as the growing role of integrated hardware-software platforms in driving recurring revenue and margin expansion.